OSE Immunotherapeutics Unveils Promising Phase 2 Data for Lusvertikimab in Ulcerative Colitis

OSE Immunotherapeutics has presented full efficacy and safety data from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127) at the 20th Congress of ECCO (European Crohn’s and Colitis Organisation). The randomized, double-blind, placebo-controlled trial demonstrated significant improvements in ulcerative colitis (UC) patients, with high rates of endoscopic remission, histological improvement, and mucosal healing achieved within just 10 weeks of treatment. These findings offer a strong indication of Lusvertikimab’s potential as a breakthrough therapy for moderate to severe UC.

Experts in the field, including Pr. Arnaud Bourreille of Nantes University Hospital and Pr. Walter Reinisch of the Medical University of Vienna, emphasized the study’s key outcomes, highlighting the reduction of fecal calprotectin (FCP)—a vital biomarker for inflammation. The data reinforce Lusvertikimab’s potential as a transformative treatment option, offering UC patients a promising new avenue for sustained remission and improved long-term outcomes.